Treatment of fistulas in Crohn's disease with infliximab

Gut

Volumn 45, Issue 5, 1999, Pages 642-643

  Lofberg R ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ABSCESS; ADULT; AGED; CLINICAL TRIAL; COLON CROHN DISEASE; COLON FISTULA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; NOTE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032693650     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.45.5.642     Document Type: Note

References (2)

1. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Eng J Med 1997;337:1029-35.
2. Smolen JS, Steiner G, Breedveld FC, et al. Anti-TNFα therapy and drug induced lupus-like syndrome [abstract]. XIV EULAR Congress 1999 Abstract Book. London: BMJ Publishing Group, 1999: p217, A906.